FDA grants emergency use authorization for InflaRx's Gohibic (vilobelimab) for COVID-19 treatment.
TL;DR Summary
The FDA has granted emergency use authorization for Gohibic (vilobelimab) injection for the treatment of COVID-19 in hospitalized adults who have received invasive mechanical ventilation or extracorporeal membrane oxygenation. The treatment targets a part of the immune system that is thought to play a role in the inflammation that leads to COVID-19 disease progression. Clinical trials showed that patients treated with Gohibic had a lower risk of death by day 28 and day 60 of treatment compared to placebo.
- FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19 FDA.gov
- FDA authorizes InflaRx's anti-inflammation drug for most serious COVID despite phase 3 miss FiercePharma
- InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients Yahoo Finance
- InflaRx's Gohibic Gets Emergency Use Authorization from FDA for Covid-19 Hospitalized Patients MarketWatch
- InflaRx up 60% on FDA OK of COVID-19 drug vilobelimab Seeking Alpha
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
73%
297 → 79 words
Want the full story? Read the original article
Read on FDA.gov